South Korea's regulatory authorities are making diverse efforts to enable the more rapid introduction of novel therapies to the country. as part of a broad goal of improving patients’ access to medical innovation.
As part of this, the Ministry of Food and Drug Safety (MFDS) has now selected Roche Holding AG’s Lunsumio (mosunetuzumab) as the first product to be reviewed under its...